Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)Dermatomyositis (DM)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)
Interventions
DRUG

RAY121

Injection

Trial Locations (54)

1083

Semmelweis Egyetem, Budapest

1090

AKH - Medizinische Universitaet Wien, Abteilung fuer Klinische Pharmakologie, Vienna

1202

Diagnostic Consultation Center CONVEX EOOD, Sofia

1307

Universitaetsklinikum Carl Gustav Carus TU Dresden, Klinik und Poliklinik f. Dermatologie, Sachsen

1756

"SHATHD EAD Sofia", Sofia

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Sydney

2560

Campbelltown Public Hospital, Sydney

3004

The Alfred Hospital, Melbourne

3075

Universitaetsmedizin Goettingen, Göttingen

3128

Box Hill Hospital, Melbourne

4011

Stavanger Universitetssjukehus, Stavanger

4604

Sorlandet sykehus Kristiansand, Kristiansand

6003

"UMHAT Prof. Dr. St. Kirkovich, AD", Stara Zagora

6720

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged

10000

"Clinical Hospital Center Sestre Milosrdnice", Zagreb

University hospital centre Zagreb, Zagreb

10154

Ospedale San Giovanni Bosco, Torino

11000

Sanatorium Profesora Arenbergera, Prague

11658

Oncology Institute Prof. Dr. Ion Chiricuta I.O.C.N., Cluj-Napoca

14004

Hospital Universitario Reina Sofia, Córdoba

20089

Istituto Clinico Humanitas, Milan

23538

Universitaetsklinikum Schleswig Holstein - Campus Luebeck, Klinik f Dermatologie, Allergologie u Venerologie, Lübeck

28027

Clinica Universidad de Navarra, Pamplona

28034

Hospital Universitario Ramon y Cajal, Servicio de Reumatologia, Madrid

28041

Hospital Universitario 12 de October, Madrid

34093

Istanbul University Istanbul Medical Faculty, Istanbul

34295

Hopital Lapeyronie,Service d'Immuno Rhumatologie, Montpellier

41013

Hospital Universitario Virgen del Rocio, Seville

46026

Hospital Universitari i Politecnic La Fe, Valencia

47014

"IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori - IRST", Meldola

51000

Specialty Hospital Medico, Rijeka

72076

Universitaetsklinikum Tuebingen, Tübingen

75013

AP-HP Hôpital Universitaire Pitié Salpêtrière, Paris

91054

Universitaetsklinikum Erlangen, Erlangen

100229

National Taiwan University Hospital, Taipei

400015

Centrul Medical Monza SRL, Bucharest

407219

Taichung Veterans General Hospital, Taipei

J1L 0H8

DiIEX Recherche Sherbrooke, Inc, Sherbrooke

060-0808

Hokkaido University Hospital, Sapporo

980-8574

Tohoku University Hospital, Sendai

589-8511

Kindai University Hospital, Sayama

565-0871

Osaka University Hospital, Suita

431-3192

Hamamatsu University Hospital, Hamamatsu

187-8551

National Center of Neurology and Psychiatry, Kodaira

134-8540

Toho University Omori Medical Center, Ōta-ku

700-8558

Okayama University Hospital, Okayama

9713 GZ

University Medical Centre Groningen UMCG, Groningen

3584 CX

UMC Utrecht, Utrecht

02-637

Institute Reumatologii I'm. Eleonory Reicher, Warsaw

471-243

Centro Clinico Academico Braga, Braga

4434-502

Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia

08035

Hospital Universitari Vall d'Hebron, Internal Medicine Dept., Barcelona

06200

Dr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY

NCT06723106 - Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) | Biotech Hunter | Biotech Hunter